evipedia.ai
← Back

Thiamine for Health & Longevity

Evidence Review created on 11/01/2026 using AI4L / Opus 5.5

Also known as: Vitamin B1, Thiamin, Aneurin, Thiamine Hydrochloride, Thiamine Mononitrate

Motivation

Thiamine (vitamin B1) is an essential vitamin that the body cannot make and stores only in small amounts. In its active form it allows key enzymes to turn carbohydrates, fats and protein into usable energy, which makes the brain, nerves and heart especially dependent on a steady supply. It occurs in whole grains, legumes, pork and fortified flour, and is sold as an inexpensive supplement and as a fat-soluble synthetic version called benfotiamine.

A severe shortage causes beriberi, a once-common deficiency disease, and a brain disorder seen in heavy drinkers; both shaped the early history of nutrition science. Attention has since moved to milder, hidden shortfalls in people with diabetes, people taking fluid-removing medications, heavy drinkers and frail older adults, and researchers have tested doses far above dietary needs for heart function, nerve damage in diabetes and memory decline.

This review examines what human studies show about thiamine and benfotiamine supplementation beyond preventing deficiency: which benefits and risks are supported, at what level of evidence, and how dosing, testing and sourcing are handled in practice by health-focused adults aiming to protect long-term brain, heart and metabolic health.

Benefits - Risks - Protocol - Conclusion

Selected overviews and research articles that discuss thiamine or its derivatives in depth.

No dedicated thiamine content was found from Peter Attia, Andrew Huberman or Lifespan.io; Rhonda Patrick addresses thiamine only briefly, in members-only Q&A segments and in passing within a free episode on alcohol (FoundMyFitness alcohol episode), and Chris Kresser’s site mentions it only in passing within broader articles.

Grokipedia

Thiamine

An AI-written encyclopedia entry on thiamine’s biochemistry, dietary sources and deficiency; useful as a quick general reference, though its claims need checking against primary sources.

Examine

Thiamine (Vitamin B1)

Examine’s independent supplement page summarizing human research on thiamine’s benefits, dosage and side effects, useful for checking claims against graded study summaries.

ConsumerLab

B Vitamin Supplements Review (B Complexes, B6, B12, Biotin, Folate, Niacin, Riboflavin & More)

ConsumerLab’s independent label-accuracy testing of B vitamin products, including Top Picks for thiamin and for benfotiamine; full results are members-only, while the summary is public.

Systematic Reviews

Systematic reviews and meta-analyses (statistical pooling of several studies) of thiamine supplementation, chosen for size, recency and relevance to its main claimed uses.

No systematic review or meta-analysis addresses thiamine’s principal risk, hypersensitivity reactions to injected thiamine, so that side of the trade-off is unrepresented here.

Mechanism of Action

Thiamine is absorbed in the small intestine by thiamine transporters 1 and 2 (encoded by the SLC19A2 and SLC19A3 genes, which move thiamine into cells) and, at high doses, passive diffusion (Smithline 2012). Inside cells it becomes thiamine diphosphate (TDP, the active coenzyme form), which several enzymes require (Whitfield 2018):

  • Pyruvate dehydrogenase and α-ketoglutarate dehydrogenase: mitochondrial complexes feeding glucose-derived fuel into energy production; deficiency stalls ATP (cellular energy) synthesis and raises lactate (a by-product of oxygen-starved metabolism), so brain, nerve and heart cells fail first.
  • Transketolase: an enzyme of the pentose phosphate pathway (a glucose side route making DNA building blocks and antioxidant defenses).
  • Branched-chain α-keto acid dehydrogenase: breaks down leucine, isoleucine and valine.

Pharmacology: free thiamine’s plasma half-life (time for levels to halve) is 96 minutes intravenously and 154 orally, TDP’s about 11 hours, and oral bioavailability (share reaching blood) of 50 mg was 5.3% (Tallaksen 1993). It circulates mainly in red cells, reaching brain, liver, heart and muscle (Whitfield 2018). It bypasses cytochrome P450 (drug-metabolizing) enzymes; the liver takes it up through OCT1 (organic cation transporter 1, also used by metformin) (Chen 2014); excess is excreted.

Benfotiamine: a synthetic derivative giving higher blood thiamine than thiamine salts, per a review (Loew 1996). In diabetic rats it activated transketolase and blocked glucose-driven damage, including advanced glycation end products (AGEs, harmful sugar–protein complexes) (Hammes 2003). Competing finding: in mice it raised thiamine in blood and liver but not brain (Volvert 2008), so brain effects may be indirect.

Historical Context & Evolution

Beriberi spread across rice-eating Asia in the 19th century as steam mills polished away the thiamine-rich bran. In 1884 the Japanese naval surgeon Kanehiro Takaki cut beriberi in sailors by changing their diet, which he attributed to protein. In Java, Christiaan Eijkman observed that chickens fed white rice developed leg paralysis while those fed unpolished rice did not, and Gerrit Grijns concluded that foods contain unknown substances needed by the nerves; Barend Jansen and Willem Donath crystallized the curative factor (“aneurin”) in 1926, and Robert Williams synthesized it in 1936, per a historical review (Carpenter 2012). In the 1880s, Wernicke and Korsakoff had described the brain syndromes later traced to thiamine deficiency.

The original intended use was prevention and treatment of deficiency. Field trials of enriched rice in the Philippines (Salcedo 1950) and flour fortification in many countries followed. In Japan, the discovery of a garlic-derived fat-soluble form in the 1950s led to synthetic derivatives, including benfotiamine.

Interest in health optimization grew from three observations: long-term diuretic (urine-increasing medication) users and people with diabetes lose thiamine in urine (Seligmann 1991; Thornalley 2007); benfotiamine blocked glucose-driven tissue damage in animals (Hammes 2003); and Derrick Lonsdale argued that marginal deficiency is common (Marrs 2021) while Antonio Costantini reported high-dose responses (Costantini 2015). Opinion has shifted both ways: small early heart-failure trials were positive (Shimon 1995), later larger ones were null (Keith 2019), while high-dose fatigue trials produced new positive and null results (Bager 2021; Bager 2024). None of these questions is settled.

Expected Benefits

High 🟩 🟩 🟩

Shorter shock and fewer complications in critical illness ⭕️ Not Central to Health & Longevity ⚠️ Conflicted

Intravenous thiamine may shorten shock (dangerously low blood pressure starving organs of blood). Meta-analyses of randomized trials by independent groups found shorter shock (Nakanishi 2024), less delirium (acute confusion) (Sedhai 2021) and, with thiamine alone, less dialysis in sepsis (a body-wide reaction to infection that damages organs) (Xu 2026). An 88-patient septic shock (infection-driven shock) trial found no overall lactate or shock-reversal benefit (Donnino 2016). This bears on acute hospital care, not long-term health. Net, pooled data suggest modest organ-support effects but no survival gain.

Magnitude: Shock lasted 11.43 hours less than in controls (95% confidence interval, CI, the range likely to contain the true effect: −20.16 to −2.69 hours) and lactate was 0.34 mmol/L lower (95% CI −0.63 to −0.05); mortality risk ratio (RR, risk with thiamine divided by risk with control) 0.89 (95% CI 0.75 to 1.06) (Nakanishi 2024); intensive-care delirium odds ratio (OR, odds with thiamine divided by odds with control) 0.58 (95% CI 0.34 to 0.98) in randomized trials (Sedhai 2021); odds ratio for renal replacement therapy (dialysis) 0.26 in sepsis trials of thiamine alone (Xu 2026).

Medium 🟩 🟩

Prevention and correction of thiamine deficiency disorders

Adequate thiamine prevents beriberi (deficiency causing heart failure or nerve damage) and Wernicke–Korsakoff syndrome (confusion, eye-movement and gait problems progressing to lasting memory loss). Evidence comes from comparisons with control areas or periods: enriched rice in a Philippine field trial (Salcedo 1950) and Australian flour fortification (Harper 1998). Randomized evidence is too thin to set treatment dose (Day 2013). Relevance centers on heavy drinkers, people after weight-loss surgery, diuretic users, people with diabetes and frail older adults.

Magnitude: Autopsy prevalence of Wernicke–Korsakoff syndrome was 1.1% (25 of 2,212) after flour fortification, reported as significantly lower than earlier pre-fortification autopsy series (historical comparison, no concurrent control group) (Harper 1998).

Menstrual pain relief

Primary dysmenorrhea (menstrual cramping without underlying disease) is the outcome. A 120-woman placebo-controlled trial pooled by Cochrane favored vitamin B1 (Pattanittum 2016); a larger Indian crossover trial (each participant receives both treatments in turn) of 556 young women given 100 mg/day reported 87% cured but only after both groups had received thiamine, without a between-group comparison (Gokhale 1996). Cochrane rated the evidence low quality. The mechanism is unestablished, and the finding applies only to women with painful periods.

Magnitude: Pain 2.70 points lower than placebo on a 0–10 visual analogue scale (a line on which pain is rated) (95% CI −3.32 to −2.08; one trial, 120 women) (Pattanittum 2016).

Reduced fatigue in chronic inflammatory disease ⚠️ Conflicted

In inflammatory bowel disease (IBD, Crohn’s disease or ulcerative colitis) in remission with severe fatigue, 600–1,800 mg/day oral thiamine for four weeks reduced fatigue versus placebo in a 40-patient crossover trial (Bager 2021). The same Danish group found no benefit with an identical design in primary biliary cholangitis (an autoimmune liver disease) (Bager 2024). The proposed mechanism, a functional thiamine shortfall despite normal blood levels, is unproven. Net, benefit is shown only for IBD-related fatigue and awaits replication by another group.

Magnitude: In IBD, fatigue fell 4.5 points (95% CI 2.6 to 6.2) after thiamine versus a 0.75-point rise after placebo, P = 0.0003 (P, the probability of a difference this large arising by chance) (Bager 2021); in primary biliary cholangitis, fatigue rose 0.3 points after thiamine versus a 1.4-point fall after placebo, P = 0.55 (Bager 2024).

Reduced urinary albumin in diabetic kidney disease ⚠️ Conflicted

In type 2 diabetes with microalbuminuria (small urinary protein leaks signaling early kidney damage), 300 mg/day thiamine lowered urinary albumin versus placebo in 40 patients (Rabbani 2009). Benfotiamine 900 mg/day, an indirect form, did not in an 82-patient trial supplied by manufacturer Wörwag Pharma (Alkhalaf 2010). Net, one direct thiamine trial supports the benefit, the null benfotiamine trial does not refute it, and replication with thiamine is lacking.

Magnitude: Urinary albumin excretion 30.1 versus 35.5 mg/24 h after three months of thiamine versus placebo (P < 0.01) (Rabbani 2009); no significant reduction with benfotiamine (Alkhalaf 2010).

Low 🟩

Improved heart function in heart failure ⚠️ Conflicted

Small early trials in diuretic-treated heart failure found higher ejection fraction (share of blood pumped out per beat) (Shimon 1995; Schoenenberger 2012). A larger 6-month trial found none (Keith 2019), and a seven-trial meta-analysis was null (He 2024). Net, benefit beyond correcting deficiency is unlikely.

Magnitude: Pooled ejection fraction change 1.65 percentage points versus placebo (95% CI −1.10 to 4.41; seven trials, 274 patients) (He 2024).

Relief of diabetic nerve symptoms ⚠️ Conflicted

Indirect: tested benfotiamine, a synthetic thiamine precursor, not thiamine salts. Short trials improved polyneuropathy (damage to many peripheral nerves) symptom scores (Haupt 2005; Stracke 2008, co-authored by an employee of manufacturer Wörwag Pharma); a 12-month trial, also with Wörwag co-authors, found no effect (Ziegler 2026). Net, durable benefit is unproven.

Magnitude: After 12 months, Neuropathy Symptom Score 0.98 points lower than with placebo (95% CI −2.15 to 0.18; P = 0.098, not significant) (Ziegler 2026); after 6 weeks, symptom scores improved more than with placebo only in the per-protocol analysis (limited to participants who completed treatment as planned; P = 0.033), its abstract reporting no between-group effect size (Stracke 2008).

Slower cognitive decline in early Alzheimer’s disease

Indirect: tested benfotiamine 600 mg/day, not thiamine. In 70 people with mild cognitive impairment or mild Alzheimer’s dementia, 12 months of treatment did not significantly slow the primary cognitive score but slowed worsening on the Clinical Dementia Rating (Gibson 2020). A 406-person trial is under way (NCT06223360).

Magnitude: Increase in the Alzheimer’s Disease Assessment Scale–Cognitive score 43% smaller than with placebo (P = 0.125, not significant); worsening on the Clinical Dementia Rating 77% smaller (P = 0.034) (Gibson 2020).

Improvement in Parkinson’s disease symptoms

An open-label series (no placebo; patients and clinicians knew the treatment) gave 100 mg intramuscular thiamine twice weekly to 50 people with Parkinson’s disease and reported large motor and non-motor improvements (Costantini 2015). Without blinding or a control group, placebo response cannot be excluded; no randomized trial exists.

Magnitude: Unified Parkinson’s Disease Rating Scale total score fell from 38.6 to 18.2 within three months (no control group) (Costantini 2015).

Lower stroke risk with higher dietary intake

Indirect: measured thiamine from food, not supplements. Among 121,565 women in the Women’s Health Initiative followed for a median 18.4 years, the highest intake fifth had lower stroke risk than the lowest (Zhang 2026). Confounding (distortion by linked factors such as overall diet quality) is likely.

Magnitude: Hazard ratio (HR, relative rate of stroke over time) 0.84 (95% CI 0.76 to 0.92), highest versus lowest intake fifth (Zhang 2026).

Lower depression risk with higher dietary intake

Indirect: measured thiamine from food, not supplements. A meta-analysis of observational studies found lower depression risk with the highest versus lowest dietary vitamin B1 intake (Wu 2022). Confounding by diet quality is likely; one 51-patient trial found add-on thiamine improved depression at six weeks, not significantly at twelve (Ghaleiha 2016).

Magnitude: Pooled relative risk 0.69 (95% CI 0.55 to 0.87), highest versus lowest intake category (Wu 2022).

Lower colorectal cancer risk with higher intake

Indirect: observational intake data, not supplementation trials. A meta-analysis of one cohort and six case-control studies (comparing patients with healthy controls; 6,184 cases) found lower colorectal cancer risk at the highest versus lowest vitamin B1 intake (Liu 2021). Case-control designs are prone to recall bias (misremembered past diet).

Magnitude: Pooled odds ratio (OR, the odds of cancer in high- versus low-intake groups) 0.76 (95% CI 0.65 to 0.89) (Liu 2021).

Speculative 🟨

Protection against glycation damage

In diabetic rats, benfotiamine activated transketolase and blocked three glucose-driven damage pathways, preventing retinopathy (retinal blood-vessel damage) (Hammes 2003). Human data are limited to unvalidated blood glycation markers; the basis is mechanistic.

Higher high-density lipoprotein cholesterol in type 2 diabetes

Pooled trials found HDL (high-density lipoprotein, the so-called “good” cholesterol) rose slightly, while glucose control was unchanged (Muley 2022). Raising HDL is an unvalidated biomarker change, not a proven route to fewer cardiovascular events.

Benefit-Modifying Factors

  • Genetic polymorphisms: Rare SLC19A2 or SLC19A3 transporter mutations cause disorders that respond to high-dose thiamine, per a review (Brown 2014). Benfotiamine’s dementia-trial effects were stronger without APOE4 (Alzheimer’s main risk variant of the gene for apolipoprotein E, a cholesterol-carrying protein) (Gibson 2020).
  • Baseline biomarker levels: Benefits concentrate in people with low status: in septic shock, lactate fell only in thiamine-deficient patients (Donnino 2016), whereas heart-failure patients not selected for deficiency gained nothing (Keith 2019).
  • Sex-based differences: The menstrual-pain benefit is specific to women. The largest heart-failure trial enrolled 83% men (Keith 2019), and no trial has tested sex differences in response.
  • Pre-existing health conditions: Diabetes raises kidney clearance of thiamine (its removal from blood into urine) 16- to 24-fold and lowers plasma thiamine about 75% (Thornalley 2007); long-term furosemide use, heavy drinking and weight-loss surgery also deplete thiamine, making correction more likely to help.
  • Age-related considerations: Among community-dwelling older adults admitted to hospital, 48% had marginal or definite deficiency, linked to delirium (acute confusion) (O’Keeffe 1994), so benefit from correction is more likely at older ages.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: placebo-controlled trials of oral thiamine and benfotiamine show adverse-event rates similar to placebo, and serious reactions are documented only in uncontrolled case series and case reports of injected thiamine.

Medium 🟥 🟥

No risk reaches Medium: the harms identified rest on a label statement without data, uncontrolled case series and case reports, indirect dietary observational data, or animal experiments, and no controlled study has shown excess harm.

Low 🟥

Hypersensitivity reactions to injected thiamine

Injected thiamine can cause allergic reactions, rarely anaphylaxis (severe, life-threatening allergy), including cardiac arrest (Juel 2013). The UK Summary of Product Characteristics (SmPC, regulator-approved label) warns of this and of contact dermatitis (allergic skin rash) (Thiamine injection SmPC). In 989 patients, nearly all reactions were local irritation (Wrenn 1989).

Magnitude: 12 reactions per 1,070 intravenous 100 mg doses (1.1%): 11 local irritation and 1 generalized itching (0.093%); no control group (Wrenn 1989).

Mild adverse effects at high oral doses ⚠️ Conflicted

Oral thiamine at 600–1,800 mg/day had only mild side effects, not compared with placebo (Bager 2021). A 12-month placebo-controlled benfotiamine trial (Ziegler 2026) and dose-escalation studies co-authored by benfotiamine patent holder Shanghai Rixin Biotechnology (Sheng 2021) found adverse-event rates similar to placebo. Net, controlled data show no excess risk.

Magnitude: Possibly or probably drug-related adverse events in 3.6% with benfotiamine 600 mg/day versus 6.9% with placebo over 12 months (Ziegler 2026).

Toxicity with long-term oral doses above 3,000 mg/day

The UK SmPC states that long-term oral intake above 3,000 mg/day has been known to produce toxicity, without describing its form or frequency (Thiamine injection SmPC). This lies above the 600–1,800 mg/day tolerated in high-dose fatigue trials (Bager 2021). No controlled study has tested such doses long term.

Magnitude: Toxicity is reported with long-term oral intake above 3,000 mg/day; the label reports no outcome figure, and no study has measured its incidence (Thiamine injection SmPC).

Faster cognitive decline at higher dietary intake

Indirect: dietary thiamine, not supplements. In 3,106 cognitively healthy older Chinese adults followed about six years, cognitive decline accelerated above roughly 0.68 mg/day of dietary intake, a J-shaped pattern (no change at low intake, then rising risk) (Liu 2024). Residual confounding by other dietary factors may explain it.

Magnitude: Above 0.68 mg/day, each additional 1 mg/day was associated with a 4.24-point greater five-year decline in global cognitive score (95% CI 2.22 to 6.27) (Liu 2024).

Speculative 🟨

Stimulation of tumor growth

In mice with ascites tumors (cancer cells growing in abdominal fluid), thiamine at 25 times the requirement increased tumor growth 164%, while very high doses inhibited it (Comín-Anduix 2001). Basis is animal-only.

Risk-Modifying Factors

  • Genetic polymorphisms: No common gene variant is known to increase harm from supplementation; rare SLC19A2 or SLC19A3 mutation carriers need lifelong high doses without reported toxicity, per a review (Brown 2014).
  • Baseline biomarker levels: In people already deficient, glucose given before thiamine can precipitate acute deficiency, per a review (Mrowicka 2023); in replete people, urinary excretion rises sharply once kidney reabsorption is saturated, and no upper intake level exists, per a review (Whitfield 2018).
  • Sex-based differences: No sex difference in adverse effects is reported. Pregnancy’s greater danger is deficiency from hyperemesis gravidarum (severe pregnancy vomiting), which can cause Wernicke encephalopathy (Fiorentini 2023). Above 50 mg/day, the label cannot exclude risk to breastfed infants (Thiamine injection SmPC).
  • Pre-existing health conditions: Anaphylaxis risk rises with repeated injected doses (Thiamine injection SmPC), as case reports document (Stephen 1992); active cancer raises the theoretical tumor-growth concern from animal data (Comín-Anduix 2001).
  • Age-related considerations: Deficiency is common in older adults, found in 48% of older hospital admissions (O’Keeffe 1994), so under-treatment is their main risk; the J-shaped dietary cognition association was observed in older adults (Liu 2024).

Key Interactions & Contraindications

Documented interactions:

  • Loop diuretics (furosemide, bumetanide, torsemide): Long-term furosemide increases urinary thiamine loss; 21 of 23 treated heart-failure patients were deficient versus 2 of 16 controls (Seligmann 1991). Mitigation: periodic whole-blood TDP testing; 200 mg/day corrected deficiency (Shimon 1995).
  • Fedratinib (JAK2 inhibitor, blocking an overactive growth-signaling enzyme in the bone-marrow cancer myelofibrosis): US Food and Drug Administration (FDA) boxed warning for fatal Wernicke encephalopathy. Mitigation: thiamine testing before starting, repletion of deficiency and daily preventive oral thiamine (Inrebic FDA label).
  • Fluoropyrimidines and ifosfamide (cancer drugs blocking cell division; 5-fluorouracil, capecitabine, ifosfamide): The UK SmPC lists these as thiamine antagonists causing deficiency with chronic use (Thiamine injection SmPC). Mitigation: the label advises considering high-dose thiamine during treatment, weighed against the animal tumor-growth data.
  • Alcohol: Chronic heavy intake impairs intestinal thiamine absorption (Thomson 1970), causing deficiency and Wernicke–Korsakoff syndrome. Mitigation: higher supplemental doses during and after heavy drinking, plus status testing.
  • Phenytoin (anti-seizure medication): Long-term users had lower thiamine in whole blood and in cerebrospinal fluid (the fluid around the brain and spinal cord) than controls (Botez 1982), risking deficiency-related neurological symptoms. Mitigation: periodic status testing.
  • Tea, coffee, betel nut and raw fermented fish: Polyphenols (plant compounds in tea and coffee) and thiaminases (enzymes that destroy thiamine) inactivate dietary thiamine and contributed to beriberi in Thailand (Vimokesant 1982). Mitigation: separating these from thiamine-rich meals and supplements by a few hours.
  • Magnesium (supplement interaction): Magnesium is required to activate thiamine; deficiency symptoms resisted high-dose intravenous thiamine until magnesium was replaced (Dyckner 1985). Mitigation: correction of low magnesium alongside thiamine.
  • Trimethoprim (antibiotic): In a randomized crossover study in seven healthy volunteers, trimethoprim raised blood thiamine exposure, which the authors attribute to inhibition of liver uptake through OCT1 (Vora 2023); reduced liver thiamine uptake is the possible consequence, unmeasured clinically. Mitigation: status testing during prolonged courses.
  • Sulfite-preserved foods and drinks: Sulfites cleave thiamine chemically, reducing the amount absorbed from those foods; FDA rules bar the sulfiting agent sodium bisulfite from foods recognized as a source of vitamin B1 (FDA 21 CFR 182.3739). Mitigation: sulfite-treated foods are not counted as thiamine sources.
  • Metformin: In FDA adverse-event reports, metformin was among the five drugs most often linked to thiamine deficiency (Du 2026); cell and mouse studies show it inhibits intestinal and liver thiamine transporters (Liang 2015; Chen 2014). Mitigation: periodic TDP testing in long-term users.
  • Metronidazole (antibiotic): In the same FDA adverse-event analysis, metronidazole was also among the five drugs most often reported with thiamine deficiency (Du 2026), a risk of deficiency-related neurological symptoms. Mitigation: status testing during prolonged or repeated courses.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Over-the-counter and prescription transporter inhibitors (famotidine, chloroquine, verapamil): Inhibited transporter-2-mediated thiamine uptake in cells (Liang 2015), with possible reduced absorption. Mitigation: dosing separated by several hours.
  • Alpha-lipoic acid, riboflavin and niacin (additive): Alpha-lipoic acid and the coenzyme forms of riboflavin (vitamin B2) and niacin (vitamin B3) work in the same pyruvate and α-ketoglutarate dehydrogenase complexes, so combined use may add to energy-metabolism effects; no human interaction data exist.

Populations who should avoid Thiamine:

  • People with known hypersensitivity to thiamine or any inactive ingredient, for injectable products (Thiamine injection SmPC).
  • People with a prior anaphylactic reaction to injected thiamine, for further injected doses outside a setting equipped for resuscitation (Juel 2013).
  • People with active cancer considering doses far above requirements: inferred from tumor-growth stimulation in mice; no human data (Comín-Anduix 2001).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Oral rather than injected routine use: Avoids the injection-related anaphylaxis documented with intravenous thiamine (Juel 2013; Wrenn 1989).
  • Supervised, slow injections: The label advises diluted intravenous infusion over 30 minutes with resuscitation facilities available, mitigating anaphylaxis and cardiac arrest (Thiamine injection SmPC).
  • Thiamine before glucose when deficiency is likely: Prevents glucose loading from precipitating Wernicke encephalopathy in malnourished or heavy-drinking people, per a review (Mrowicka 2023).
  • Split high doses and take with meals: Dividing 600–1,800 mg/day into two or three doses limits the mild side effects reported at these doses.
  • Ceiling on long-term oral dose: Keeping long-term oral intake below 3,000 mg/day, above which the label reports toxicity, avoids that risk (Thiamine injection SmPC).
  • Avoiding large multiples during active cancer: Keeping doses well below 25 times the requirement during cancer treatment avoids the dose that most stimulated tumor growth in mice; lower doses were not shown to be safe (Comín-Anduix 2001).
  • Cognitive tracking in older long-term users: Periodic memory and concentration checks every 6–12 months address the unexplained link between higher dietary intake and faster cognitive decline (Liu 2024).

Therapeutic Protocol

Doses below are cited to their sources; other parameters (timing, splitting, duration, titration) reflect common practice.

  • Dietary requirement: 1.2 mg/day for men and 1.1 mg/day for women, rising to 1.4 mg/day in pregnancy, with no upper intake level (Whitfield 2018).
  • Conventional approach: Supplements only to correct or prevent deficiency in at-risk groups; 200 mg/day orally in heart failure (Keith 2019) and 100 mg/day for menstrual pain (Gokhale 1996).
  • High-dose approach: 600–1,800 mg/day oral thiamine hydrochloride, set by sex and body weight, tested for fatigue (Bager 2021); Italian neurorehabilitation physician Antonio Costantini popularized high-dose thiamine, using 100 mg intramuscularly twice weekly in Parkinson’s disease (Costantini 2015).
  • Benfotiamine approach: 300–600 mg/day for diabetic nerve symptoms (Stracke 2008); 300 mg twice daily in the dementia trial (Gibson 2020); promoted by Life Extension, which sells it (Life Extension explainer).
  • Suspected Wernicke encephalopathy: High-dose injected thiamine in hospital; no randomized trial defines the dose (Day 2013).
  • Time of day: Morning or midday with meals is common practice; no study has compared dosing times.
  • Half-life: Free thiamine’s plasma half-life is about 1.5–2.5 hours and thiamine diphosphate’s about 11 hours (Tallaksen 1993); blood thiamine accumulates about two-fold with repeated benfotiamine dosing (Sheng 2021).
  • Single versus split doses: Active absorption saturates at low doses while passive absorption continues at high doses (Smithline 2012); doses above about 100 mg are commonly split twice or three times daily.
  • Genetic polymorphisms: SLC19A2 or SLC19A3 disorders need lifelong high doses, per a review (Brown 2014); APOE4 non-carriers responded more to benfotiamine (Gibson 2020); OCT1 genotype did not alter thiamine kinetics (Jensen 2020), and is under further study (NCT06122701).
  • Sex-based differences: High-dose regimens scale dose to sex and weight (Bager 2021); requirements are slightly lower in women and higher in pregnancy (Whitfield 2018).
  • Age-related considerations: Frequent deficiency in older hospitalized adults (O’Keeffe 1994) supports status testing and correction before high-dose experimentation at older ages.
  • Baseline biomarker levels: In septic shock, lactate fell only in thiamine-deficient patients (Donnino 2016); heart-failure patients not selected for deficiency showed no benefit (Keith 2019).
  • Pre-existing health conditions: Diabetes, loop diuretic use, heavy drinking and weight-loss surgery increase losses (Thornalley 2007; Seligmann 1991), so maintenance doses above requirements are common in these groups.

Discontinuation & Cycling

  • Lifelong versus short-term: Dietary need is lifelong; supplementation is short-term for correcting deficiency and ongoing for continuing risks such as diuretic use, diabetes or weight-loss surgery.
  • Withdrawal effects: None are known; menstrual-pain relief persisted two months after stopping 100 mg/day (Gokhale 1996).
  • Tapering: Not required pharmacologically; high-dose users commonly step down to a lower maintenance dose once symptoms stabilize.
  • Cycling: No evidence supports cycling; because thiamine’s half-life is short and body stores are limited (Whitfield 2018), interruptions in at-risk people can deplete status within weeks.

Sourcing and Quality

  • Forms: Thiamine hydrochloride (most supplements) and thiamine mononitrate (food fortification) are equivalent salts; benfotiamine raises blood levels more, per a review (Loew 1996); the disulfide derivative sulbutiamine raises brain thiamine, unlike benfotiamine (Volvert 2008), while fursultiamine’s brain uptake was not tested there.
  • Third-party testing: USP (United States Pharmacopeia) Verified or NSF Certified marks confirm label accuracy; ConsumerLab found 5 of 26 B vitamin products failed testing (ConsumerLab B vitamin review).
  • Combination products: B-complex products often contain niacin, folate and vitamin B6, which can cause toxicity at excessive intakes (ConsumerLab B vitamin review); single-ingredient thiamine avoids this.
  • Reputable brands: Thorne and Pure Encapsulations (thiamine hydrochloride), Life Extension and Doctor’s Best (benfotiamine), and Ecological Formulas Lipothiamine (fursultiamine) are widely used examples.
  • Stability: Thiamine degrades with heat, alkaline conditions and sulfites; capsules are best stored cool and dry.

Practical Considerations

  • Time to effect: Deficiency signs can improve within hours to days of treatment, per a review (Whitfield 2018); fatigue responses were measured at four weeks (Bager 2021), nerve symptoms at three to six weeks (Haupt 2005; Stracke 2008), and cognition over 12 months (Gibson 2020).
  • Common pitfalls: Relying on serum thiamine instead of whole-blood TDP, taking thiamine with tea or coffee, ignoring magnesium status, and expecting gains when status is already adequate.
  • Regulatory status: Injectable thiamine hydrochloride is a prescription-only medicine in the UK (Thiamine injection SmPC); oral thiamine and benfotiamine are sold widely as supplements.
  • Cost and accessibility: Thiamine is inexpensive and widely available; benfotiamine and fursultiamine cost more but remain accessible.

Interaction with Foundational Habits

  • Sleep: Direction: none documented. No controlled study has measured sleep with thiamine alone; deficiency is linked to delirium in older adults (O’Keeffe 1994). Practical: morning or midday dosing is common practice.
  • Nutrition: Direction: direct. Urinary losses rise once intake exceeds 0.3–0.4 mg per 1,000 kcal, linking needs to energy intake, per a review (Whitfield 2018); heavy alcohol use impairs absorption (Thomson 1970), and tea, coffee and raw fish reduce availability (Vimokesant 1982). Practical: whole grains, legumes, pork and fortified foods supply thiamine.
  • Exercise: Direction: indirect. Thiamine diphosphate is required for carbohydrate metabolism (Whitfield 2018), so high training volumes raise needs; no controlled evidence of performance gains in replete athletes was identified. Practical: no timing around workouts is established.
  • Stress management: Direction: indirect. No study links thiamine to cortisol; the fatigue benefit in inflammatory bowel disease (Bager 2021) may affect perceived stress burden. Practical: fatigue questionnaires can track response alongside stress practices.

Monitoring Protocol & Defining Success

Before starting high-dose or long-term supplementation, baseline testing establishes thiamine status and rules out factors that blunt response. A whole-blood thiamine diphosphate measurement taken before the first dose separates true deficiency from adequate status, and a serum magnesium check identifies a cofactor shortfall that can make thiamine ineffective. People taking loop diuretics, fedratinib or long-term metformin, and those after weight-loss surgery, have the clearest reason for baseline testing.

Ongoing monitoring follows a set cadence: repeat whole-blood thiamine diphosphate at 4–8 weeks after starting or changing a high dose, then every 6–12 months while risk factors persist, and at any new symptoms such as confusion or tingling. Fedratinib users follow the label schedule. Success is defined as normalized status plus improvement in the symptom that prompted use.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Whole-blood thiamine diphosphate (TDP) 70–180 nmol/L (standard reference range) Expected to change; confirms repletion Expected healthy range per Whitfield 2018; measured by HPLC (high-performance liquid chromatography, a laboratory separation method); fasting not required; serum thiamine reflects recent intake only
Erythrocyte transketolase activity coefficient (ETKAC) No established target; track change from own baseline Expected to change; shows functional thiamine status ETKAC (red-cell enzyme activation by added TDP); a coefficient near 1.25 marked the deficiency inflection point in at-risk patients, per a review (Whitfield 2018); offered by few laboratories
Serum magnesium 0.70–1.00 mmol/L (standard reference range) Safety check; low values make thiamine ineffective and change use Deficiency symptoms resisted thiamine until low magnesium was corrected (Dyckner 1985); ranges vary by laboratory; red-cell magnesium is a possible paired test

Qualitative markers of response:

  • Energy and fatigue, rated with a fatigue questionnaire at baseline and after four weeks
  • Menstrual pain intensity on a 0–10 scale across several cycles
  • Tingling, burning or numbness in the feet and hands
  • Memory, concentration and mental clarity
  • Appetite, mood and any palpitations or sleep disturbance at high doses

Emerging Research

  • Thiamine in ischemic heart failure (NCT05873881): Phase 3, 2,500 patients with heart failure from narrowed coronary arteries, thiamine mononitrate 300 mg/day; primary endpoint time to cardiovascular death or heart-failure event; recruiting, completion 2027. Positive: heart-failure benefit would move above Low. Null: confirms no benefit beyond deficiency.
  • BenfoTeam trial in early Alzheimer’s disease (NCT06223360): Phase 2, 406 participants, benfotiamine 300 or 600 mg twice daily versus placebo, 72-week cognitive and functional endpoints; active, not recruiting, completion December 2027. Positive: cognition item rises toward Medium. Null: weakens it substantially.
  • Thiamine and blood–brain barrier in type 2 diabetes (NCT06322212): 52 participants, 500 mg/day for three months versus placebo, barrier function and cognition; recruiting, completion March 2027. Positive: supports a brain-protection role in diabetes. Null: argues against one.
  • Thiamine for alcohol-related brain injury (NCT07844720): Phase 2 open-label pilot, 60 outpatients, 500 mg twice daily for 14 days; primary endpoint plasma neurofilament light (a blood marker of nerve-cell damage); not yet recruiting. Positive: supports routine high-dose use in heavy drinkers. Null: little change.
  • Thiamine and cognition after bypass surgery (NCT06326996): 52 older adults, intravenous thiamine versus placebo; registered completion September 2026 has passed, status still listed as recruiting, no results posted. Positive: supports brain protection around heart surgery. Null: no change.
  • OCT1 genotype and thiamine kinetics (NCT06122701): 36 healthy volunteers given 5–200 mg, following an earlier null genotype finding (Jensen 2020); registered completion August 2025 has passed, status still listed as enrolling by invitation, no results posted. Positive (genotype matters): dosing by genotype becomes relevant. Null: genotype can be ignored.
  • Replicating high-dose fatigue findings: The positive inflammatory bowel disease trial (Bager 2021) and null liver-disease trial (Bager 2024) need independent replication that could strengthen or weaken the fatigue item.
  • Evidence that could weaken the case: The J-shaped dietary cognition association (Liu 2024) and animal tumor-growth data (Comín-Anduix 2001) warrant study of long-term high-dose supplementation in older adults.

Conclusion

Thiamine is an essential vitamin that cells need to turn food into energy, and its synthetic relative benfotiamine is sold as a better-absorbed alternative. Its best-supported benefit, shorter shock in intensive care, bears on hospital care rather than long-term health. For long-term health, the clearest benefit is preventing and correcting deficiency, which matters most for heavy drinkers, people with diabetes, people on long-term fluid-removing medications, those after weight-loss surgery and frail older adults; enriched foods and supplements have reduced deficiency diseases where they were common.

Beyond deficiency, the picture is mixed. Small studies suggested help for menstrual pain, fatigue in bowel inflammation, nerve symptoms and kidney changes in diabetes, and memory decline, but larger or repeated studies were often neutral. Heart-failure trials, taken together, showed no real gain for people who were not deficient, and blood sugar control did not change.

Risks by mouth appear minimal, with side effects in controlled trials no more frequent than with placebo. Injections rarely cause severe allergic reactions. Animal data on tumor growth and an unexplained link between higher food intake and faster memory decline in older adults remain open questions.

The evidence base is small, often short-term, and partly produced or funded by companies that make or sell benfotiamine, and some popular high-dose approaches rest on clinical reports without comparison groups. For health-focused adults, the clearest evidence concerns adequate thiamine status, especially where known causes of depletion exist; gains beyond adequacy remain uncertain.

Top - Benefits - Risks - Protocol